Literature DB >> 12097567

Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles.

D Marsac1, D Loirat, C Petit, O Schwartz, M-L Michel.   

Abstract

In vivo priming of cytotoxic T lymphocytes (CTL) by DNA injection predominantly occurs by antigen transfer from DNA-transfected cells to antigen-presenting cells. A rational strategy for increasing DNA vaccine potency would be to use a delivery system that facilitates antigen uptake by antigen-presenting cells. Exogenous antigen presentation through the major histocompatibility complex (MHC) class I-restricted pathway of some viral antigens is increased after adequate virus-receptor interaction and the fusion of viral and cellular membranes. We used DNA-based immunization with plasmids coding for human immunodeficiency virus type 1 (HIV-1) Gag particles pseudotyped with vesicular stomatitis virus glycoprotein (VSV-G) to generate Gag-specific CTL responses. The presence of the VSV-G-encoding plasmid not only increased the number of mice displaying anti-Gag-specific cytotoxic response but also increased the efficiency of specific lysis. In vitro analysis of processing confirmed that exogenous presentation of Gag epitopes occurred much more efficiently when Gag particles were pseudotyped with the VSV-G envelope. We show that the VSV-G-pseudotyped Gag particles not only entered the MHC class II processing pathway but also entered the MHC class I processing pathway. In contrast, naked Gag particles entered the MHC class II processing pathway only. Thus, the combined use of DNA-based immunization and nonreplicating pseudotyped virus to deliver HIV-1 antigen to the immune system in vivo could be considered in HIV-1 vaccine design.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12097567      PMCID: PMC136357          DOI: 10.1128/jvi.76.15.7544-7553.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

1.  Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants.

Authors:  J J Kim; J S Yang; T C VanCott; D J Lee; K H Manson; M S Wyand; J D Boyer; K E Ugen; D B Weiner
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.

Authors:  J zur Megede; M C Chen; B Doe; M Schaefer; C E Greer; M Selby; G R Otten; S W Barnett
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 3.  MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation.

Authors:  R N Germain
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

4.  Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion.

Authors:  J C Griffiths; S J Harris; G T Layton; E L Berrie; T J French; N R Burns; S E Adams; A J Kingsman
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

5.  Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles.

Authors:  G T Layton; S J Harris; A J Gearing; M Hill-Perkins; J S Cole; J C Griffiths; N R Burns; A J Kingsman; S E Adams
Journal:  J Immunol       Date:  1993-07-15       Impact factor: 5.422

6.  Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys.

Authors:  D H Barouch; A Craiu; M J Kuroda; J E Schmitz; X X Zheng; S Santra; J D Frost; G R Krivulka; M A Lifton; C L Crabbs; G Heidecker; H C Perry; M E Davies; H Xie; C E Nickerson; T D Steenbeke; C I Lord; D C Montefiori; T B Strom; J W Shiver; M G Lewis; N L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

7.  Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo.

Authors:  R Schirmbeck; K Melber; A Kuhröber; Z A Janowicz; J Reimann
Journal:  J Immunol       Date:  1994-02-01       Impact factor: 5.422

8.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes.

Authors:  J K Yee; A Miyanohara; P LaPorte; K Bouic; J C Burns; T Friedmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

10.  DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody.

Authors:  H L Davis; M L Michel; R G Whalen
Journal:  Hum Mol Genet       Date:  1993-11       Impact factor: 6.150

View more
  14 in total

Review 1.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions.

Authors:  Laura M Walker; Dennis R Burton
Journal:  Curr Opin Immunol       Date:  2010-03-17       Impact factor: 7.486

2.  Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice.

Authors:  S B Justin Wong; Robert F Siliciano
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  Pseudotyped single-cycle simian immunodeficiency viruses expressing gamma interferon augment T-cell priming responses in vitro.

Authors:  Yue Peng; Fan-ching Lin; Paulo H Verardi; Leslie A Jones; Michael B McChesney; Tilahun D Yilma
Journal:  J Virol       Date:  2006-12-13       Impact factor: 5.103

4.  A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice.

Authors:  Jason Gummow; Yanrui Li; Wenbo Yu; Tamsin Garrod; Danushka Wijesundara; Amelia J Brennan; Ranajoy Mullick; Ilia Voskoboinik; Branka Grubor-Bauk; Eric J Gowans
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

5.  Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.

Authors:  Steven R Wilson; Jean H Wilson; Linda Buonocore; Amy Palin; John K Rose; Jon D Reuter
Journal:  Comp Med       Date:  2008-04       Impact factor: 0.982

Review 6.  A Blueprint for HIV Vaccine Discovery.

Authors:  Dennis R Burton; Rafi Ahmed; Dan H Barouch; Salvatore T Butera; Shane Crotty; Adam Godzik; Daniel E Kaufmann; M Juliana McElrath; Michel C Nussenzweig; Bali Pulendran; Chris N Scanlan; William R Schief; Guido Silvestri; Hendrik Streeck; Bruce D Walker; Laura M Walker; Andrew B Ward; Ian A Wilson; Richard Wyatt
Journal:  Cell Host Microbe       Date:  2012-10-18       Impact factor: 21.023

Review 7.  Nanoparticle delivery systems in cancer vaccines.

Authors:  Yogita Krishnamachari; Sean M Geary; Caitlin D Lemke; Aliasger K Salem
Journal:  Pharm Res       Date:  2010-08-19       Impact factor: 4.580

8.  Abrogation of contaminating RNA activity in HIV-1 Gag VLPs.

Authors:  Ziyaad Valley-Omar; Ann E Meyers; Enid G Shephard; Anna-Lise Williamson; Edward P Rybicki
Journal:  Virol J       Date:  2011-10-06       Impact factor: 4.099

9.  Pseudotyping exosomes for enhanced protein delivery in mammalian cells.

Authors:  Conary Meyer; Joseph Losacco; Zachary Stickney; Lingxuan Li; Gerard Marriott; Biao Lu
Journal:  Int J Nanomedicine       Date:  2017-04-18

Review 10.  Cytolytic Perforin as an Adjuvant to Enhance the Immunogenicity of DNA Vaccines.

Authors:  Ashish C Shrestha; Danushka K Wijesundara; Makutiro G Masavuli; Zelalem A Mekonnen; Eric J Gowans; Branka Grubor-Bauk
Journal:  Vaccines (Basel)       Date:  2019-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.